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Simple Summary: Endometrial cancer is the most common cancer of the female reproductive tract, 
and its incidence is rising. Early diagnosis has the potential to improve survival as women can re-
ceive care at the earliest possible stage when curative treatment is likely. Current tests for endome-
trial cancer diagnosis are sequentially invasive with low patient acceptability. A detection tool based 
on minimally invasive samples such as cervico-vaginal fluid would be a major advance in the field. 
This study focuses on the potential of detecting endometrial cancer based on the proteins and pep-
tides expressed in cervico-vaginal fluid. Using Sequential window acquisition of all theoretical mass 
spectra (SWATH-MS), we present a spectral library of thousands of proteins in the cervico-vaginal 
fluid of women with or at risk of endometrial cancer. This important resource will enable the iden-
tification of endometrial cancer biomarkers in cervico-vaginal fluid and advances our knowledge 
of the role of proteomics in endometrial cancer detection. 
Abstract: Endometrial cancer is the most common gynaecological malignancy in high-income coun-
tries and its incidence is rising. Early detection, aided by highly sensitive and specific biomarkers, 
has the potential to improve outcomes as treatment can be provided when it is most likely to effect 
a cure. Sequential window acquisition of all theoretical mass spectra (SWATH-MS), an accurate and 
reproducible platform for analysing biological samples, offers a technological advance for bi-
omarker discovery due to its reproducibility, sensitivity and potential for data re-interrogation. 
SWATH-MS requires a spectral library in order to identify and quantify peptides from multiplexed 
mass spectrometry data. Here we present a bespoke spectral library of 154,206 transitions identify-
ing 19,394 peptides and 2425 proteins in the cervico-vaginal fluid of postmenopausal women with, 
or at risk of, endometrial cancer. We have combined these data with a library of over 6000 proteins 
generated based on mass spectrometric analysis of two endometrial cancer cell lines. This unique 
resource enables the study of protein biomarkers for endometrial cancer detection in cervico-vagi-
nal fluid. Data are available via ProteomeXchange with unique identifier PXD025925. 
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1. Introduction 
Endometrial cancer (EC) is the sixth most common malignancy and the 14th leading 
cause of cancer-related mortality in women globally [1]. Over 380,000 incident cases were 
diagnosed in 2018 and approximately 89,000 succumbed to their disease. Its incidence is 
projected to escalate in the coming years in tandem with the rising prevalence of obesity 
[2,3]. Over 80% of endometrial cancers are what Bokhman termed type 1 EC, where low 
grade cancers, often preceded by a precursor lesion (atypical hyperplasia (AH)), develop 
from a background of unopposed oestrogen. Type 1 tumours generally have a favourable 
prognosis compared with the less common, high grade, oestrogen-independent and clin-
ically aggressive type 2 EC [4,5]. A more pragmatic classification of EC by the Cancer Ge-
nome Atlas Research Network categorises EC into four distinct molecular subtypes: pol-
ymerase epsilon (POLE) ultramutated, microsatellite instable (MSI), copy number low and 
copy number high, and this has been shown to have prognostic implications in multiple 
studies [6,7]. 
While over 90% of women with EC initially present with postmenopausal bleeding 
(PMB), only 5–10% of women with PMB have EC [8,9]. Early detection of EC is crucial for 
good survival outcomes and will enable conservative treatment options to be offered, for 
example, to women in whom surgery is potentially hazardous [10,11]. Current EC diag-
nostic modalities such as transvaginal ultrasound scan (TVS) and endometrial biopsy 
have limitations in terms of sub-optimal specificity (TVS) and reduced acceptability from 
invasiveness and discomfort (biopsy) [11,12]. Given the anatomical continuity of the uter-
ine cavity with the lower genital tract, there is growing interest in the potential for mini-
mally-invasive sampling methodologies to enable EC detection [13]. Proximal fluids, such 
as endometrial secretions, derive from or are in direct contact with the diseased organ and 
are therefore a reliable source of cancer-derived biomarkers [14]. The dynamic range of 
biomarkers in proximal fluids is significantly reduced as compared to plasma, allowing 
better sensitivity for the detection of biologically relevant molecules [15,16]. 
In recent years, there has been growing interest in the use of high-throughput tech-
nologies for cancer biomarker discovery [14,17]. Platforms such as mass spectrometry 
(MS) based proteomics, for instance, have shown promise for facilitating the comprehen-
sive analysis of complex biological specimens to better understand both physiological and 
pathological states [18]. Although transcriptomic analyses can also be used to infer cellular 
activities, they do not truly reflect the functional phenotype of the cell nor directly corre-
late to the proteome. Proteomic analysis, on the other hand, details the phenotype or en-
dotype directly [15].  
An emerging MS-based technology of high precision and accuracy that is used to 
identify and quantify proteins is the sequential window acquisition of all theoretical mass-
spectra (SWATH-MS). SWATH-MS is highly reproducible and is a data-independent ac-
quisition (DIA) methodology with a peptide-centric data analytical strategy [19]. This pro-
teomic technique requires a spectral library of peptide transitions in order to identify and 
quantify peptides from the multiplexed mass spectrometry data. The robustness of the 
spectral library significantly impacts on the study outcome as a peptide needs to be pre-
sent in an assay library for it to be identified and quantified by SWATH MS [20]. Devel-
oping a high quality library that contains all the peptide components that are likely to be 
extracted from the MS data is therefore critical to the success of any SWATH MS-based 
study [19]. 
Here, we present a bespoke spectral library for SWATH-MS based quantification of 
proteins expressed in the cervico-vaginal fluid of postmenopausal women with, or at risk 
Cancers 2021, 13, 3804 3 of 23 
 
 
of EC. Using a data-dependent acquisition MS analysis, we generated data on 18,247 pro-
teotypic peptides. The assay also includes data on precursor and fragment ion m/z, rela-
tive ion intensities and normalised retention times. Cervico-vaginal samples were ob-
tained using a Delphi screener, a sterile, pre-packaged plastic device that is specifically 
tailored for cervico-vaginal sample collection and works by a lavage principle. A library 
based on two EC cell-lines was also generated and consists of 27,972 proteotypic peptides 
and 6003 proteins. This approach will enable biomarker discovery and validation to in-
form development of an innovative point of care test via a unique catalogue of peptides 
and proteins in the cervico-vaginal fluid of women with or at risk of EC. In addition, by 
making the raw MS data available, we offer the opportunity for data re-use and analysis 
with other state-of-the-art analytical software.  
2. Methods 
2.1. Research Ethics and Approval 
Cervico-vaginal samples from women with AH/EC (cases) and from a similar at-risk 
population who do not have EC (controls) were pooled and used for the library genera-
tion. Eligibility for inclusion is as summarised in Table 1. This study was approved by the 
North-West Greater Manchester Research Ethics Committee (reference-16/NW/0660). All 
subjects provided written informed consent prior to the collection of biological samples. 
Samples were collected and stored anonymously in accordance with the principles of the 
Declaration of Helsinki and in compliance with the Human Tissue Act, 2004. All data gen-
erated from participants medical history and collected samples were handled and stored 
in accordance with the data protection principles of the General Data Protection Regula-
tion (GDPR) 2018. Two EC cell lines (Ishikawa and HEC-1A) were used for the cell-lined 
based assay library generation. The experimental workflow is shown in Figure 1 and the 
sample pool scheme in Figure 2. 
 
Figure 1. An overview of data acquisition and spectral library generation workflow. Data acquisition: Pooled cervico-
vaginal fluid samples from 9 cancer cases, 3 AH and 7 controls were used for the library generation while two EC cell lines 
were used for the cell line-based library. Cervico-vaginal samples were separated into pellets and supernatants. Pellets 
from both cervico-vaginal fluid and EC cell lines were subjected to lysis and protein extraction. All samples were subjected 
to proteolytic digestion with trypsin, peptide fractionation using high-pH reverse phase liquid chromatography and LC-
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MS/MS analysis. Library generation: Sequence database search was done using X!Tandem while the library construction 
was performed using the OpenSWATH pipeline. Library validation: technical replicates of five cervico-vaginal samples 
were used to search the library to assess its applicability for SWATH-MS data analysis, while ten samples (five cancers 
and five controls) were used to assess the potential utility of the library for biomarker discovery in the real-world setting. 
 
Figure 2. Sample pool strategy used for library generation. This is based on both cervico-vaginal supernatant and pellet 
samples. Three AH samples were pooled together while two pools were made from five cancer samples (cancer pool 1) 
and 4 cancer samples (cancer pool 2) respectively. The seven control samples were also pooled in two, based on four 
samples (control pool 1) and three samples (control pool 2) respectively. List of pooled samples used in library generation 
are summarised in Table 2. 
Table 1. Eligibility criteria for case and control selection. 
Cases Controls 
Referred with postmenopausal bleeding Referred with postmenopausal bleeding 
Biopsy proven AH or EC 
AH and EC excluded following routine diagnos-
tic investigations, including TVS, biopsy and/or 
hysteroscopy 
Able to give informed consent Able to give informed consent 
Sample taken prior to commencement of any 
treatment, including surgery, hormone therapy 
or chemotherapy 
Sample taken prior to commencement of any 
treatment, including surgery or hormone therapy 
 
Can include those with benign pathologies such 
as benign polyp or atrophic vaginitis  
2.2. Sample Collection 
Cervico-vaginal samples were collected using a Delphi screener, a plastic device 
which is approximately 20 cm long. With participants lying supine, legs apart, knees bent 
and heels brought up to the bottom, the device was inserted into the vagina and the 
plunger pressed, releasing a small reservoir of sterile saline fluid into the vagina. Pressure 
was then taken off the plunger and the fluid collected back into the device, which was 
then removed. Following collection, samples were centrifuged at 1000× g for 10 min to 
separate cellular pellets from supernatant fractions, which were stored separately at −80 
degrees. The pellets were treated with 1 mL of red blood cell (RBC) lysis solution (BD 
CytoRich Red, Becton Dickinson, NJ, USA, re-suspended by gentle pipetting, incubated 
for 5 min at room temperature and centrifuged at 1000× g for 10 min. The RBC lysis su-
pernatant was then discarded, and the pellets washed by centrifugation at 1000× g for 5 
min with phosphate buffered saline prior to storage at −80 °C.  
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2.3. Cell Culture 
EC cell lines (Ishikawa and HEC1A) were obtained, authenticated and tested for My-
coplasma prior to usage. Cell lines were cultured in DMEM growth medium (Gibco Life 
Technologies; Thermo Fisher Scientific, Inc., Waltham, MA, USA) supplemented with 10% 
(v/v) heat inactivated fetal bovine serum (Hi-FBS) (Gibco Life Technologies) and 2 mM 
glutamine (GlutaMAX). Cells were grown in 25 cm2 or 75 cm2 culture flasks (Corning, 
Tewksbury, MA, USA) and maintained at 37 °C, 95% humidity and 5% (v/v) CO2 (Thermo 
Fisher, Waltham, MA, USA). At 80% confluence, both cell lines were harvested, and a cell 
count conducted using a haemocytometer. Subculture was conducted multiple times and 
harvested cells pooled and pelleted by centrifugation at 1500× g for five minutes and 
stored at −80 degrees pending further analyses.  
2.4. Cervico-Vaginal Fluid Supernatant Preparation 
The cervico-vaginal supernatants were concentrated using the Agilent spin concen-
trator (4 mil 30K MWCO concentrator, Agilent UK, Cheadle, UK). Using the same spin, 
buffer exchange with 25 mM ammonium bicarbonate was performed prior to protein as-
say. 
2.5. Cell Lysis/Protein Extraction 
Pellets from both EC cell lines and cervico-vaginal samples were lysed in 0.5 M TEAB 
buffer with 0.05% (w/v) SDS (Protease and Phosphatase inhibitor cocktail and Benzonase) 
and incubated for 30 min at 4 degrees. Lysates were vortexed briefly every 10 min and 
sample checked until clear of DNA. Cell line pellets were lysed in 50 uL of lysis buffer per 
106 cells while cervico-vaginal sample pellets were lysed in 500 uL of buffer. Samples were 
centrifuged at 10,000× g at 4 degrees for 10 min and supernatants collected in pre-chilled 
Eppendorf vials.  
2.6. Protein Digestion 
Protein concentration was measured using the Bradford assay (Bio-rad laboratories, 
Watford, UK). Appropriate volumes of cervico-vaginal fluid and EC cell lines lysates con-
taining 20 µg (x19) and 30 µg of protein respectively were transferred into clean Eppen-
dorf vials. Disulphide bonds were reduced by the addition of 0.1 volumes of 50 mM tris-
(2-carboxyethyl) phosphine (TCEP) to the fluid and incubation in a heating block at 60 
degrees for 1 h. Alkylation was performed using 10 mM iodoacetamide in the dark at 
room temperature for 30 min and digestion completed with trypsin (Promega, Southamp-
ton, UK) at a 10:1 protein: trypsin ratio and incubated overnight at 37 °C. 
2.7. High-pH Fractionation of Peptides 
Peptide fractionation was performed using a high pH reverse phase liquid chroma-
tography system (Agilent). Sample peptides were resuspended in 1 mL of a mixture of 
97% Buffer A (0.1% (v/v) ammonium hydroxide in water adjusted to pH 10.5) and 3% 
Buffer B (0.1% (v/v) ammonium hydroxide in pure acetonitrile adjusted to pH 10.5) and 
loaded onto a C18 reverse phase (RP) column. Peptides were eluted at 700 µL/min with a 
30-min linear gradient of acetonitrile (Fisher scientific) starting from 0.5% (v/v) buffer B to 
50% (v/v). A total of 96 fractions were collected (30 s each) for a duration of ~30 min per 
run. The collected samples were concatenated in 12 fractions + the flow through. Peptides 
were subsequently dried using a speed-vac (Genevac) and stored at −80 °C.  
2.8. DDA Mass Spectrometry for Spectral Library Generation 
For library construction, dried peptides were vigorously resuspended with 40 µL of 
loading buffer (2%ACN/0.1% formic acid and 10x iRT Biognosys in a 50:1 ratio). 5 µL (~1 
µg) of each peptide sample were subsequently trapped in a 10 cm fused silica Acclaim™ 
PepMap™ 5 µm 100 Nano-Trap Column (Thermo Scientific, Waltham, MA, USA) and 
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equilibrated with 2% buffer B (0.1% FA in 80% ACN) for 15 min at a flow rate of 300 
nL/min prior to increasing the concentration of Buffer B to 7% over 5 min and a 90 min. 
gradient (2–45% buffer B at 300 nL/min) using a U3000 RSLC high pressure nanoLC (Di-
onex). The column was re-equilibrated with 2% buffer B before the next injection. Eluting 
peptides were measured on-line by an Orbitrap Fusion Lumos Tribrid mass spectrometer 
(Thermo Scientific), operating in data-dependent acquisition mode. Peptides were ionized 
using a coated silica emitter at a potential of +1.9 kV (Thermo Fischer Scientific) and fo-
cused using an S-lens value of 60. Intact peptide ions were detected at a resolution of 
60,000 (at m/z 200) and fragment ions at a resolution of 30,000 (at m/z 200); the MS mass 
range was 350–1500 Da. Automatic gain control target settings for MS were 4 × 105 charges 
and for MS/MS 1 × 105 charges, with a maximum injection time of 50 and 120-ms respec-
tively. Peptides were selected for higher-energy C-trap dissociation fragmentation at an 
underfill ratio of 1% and a quadrupole isolation window of 1.5 Da. Precursor ions were 
fragmented at a normalized collision energy of 28. 
2.9. Building the SWATH Spectral Library 
All LC-MS/MS data obtained from the Orbitrap Fusion Lumos Tribrid mass spec-
trometer (Data Citation 1) were converted into an mzXML format, centroided and 
searched using X!Tandem (version PILEDRIVER-2015/04/01) against the full 20,271 non-
redundant canonical sequences (without isoforms) of the UniProtKB/Swiss-Prot database 
(17 December 2015) appended with iRT peptides and decoy sequences. The datasets (cer-
vico-vaginal and cell lines) were searched individually using the default X!Tandem search 
parameters with few modifications as follows: a maximum valid expectation value of 10; 
fixed residue mass modification of +57.022 for carbamidomethylated cysteine; variable 
residue mass modification of +16.0 for oxidized methionine; enzyme specificity = trypsin; 
spectrum parameters including a fragment monoisotopic mass error of 40 ppm and a par-
ent mono-isotopic mass error of ±15 ppm; spectrum conditioning parameters of 100.0 
spectrum dynamic range, total spectrum peaks 50, a minimum parent (M + H) + of 400.0, 
and a minimum fragment m/z of 150. SpectraST, operating in a library generation mode, 
was used for consensus library generation while the TargetedFileConverter tool from the 
OpenSWATH workflow was used to convert TSV files to TraML format. Decoys were 
subsequently appended to the TraML assay using the OpenSwathDecoyGenerator tool 
operating in a reverse mode with an identity threshold of 1 and a similarity threshold of 
0.05 Da. The consensus assay library was subsequently converted into a Transitions 
Markup Language (TraML) file format for downstream analysis.  
2.10. Assay Library False Discovery Rate Control 
We applied a target decoy database to adjust the assay library to an FDR of 1%, giving 
rise to a 0.99% probability cut-off [21]. 
2.11. SWATH-MS Acquisition and Library Validation 
MS analysis of cervico-vaginal fluid samples used for library validation was per-
formed using a 6600 TripleTOF (Sciex, Warrington, UK). The LC method was based on a 
120-min gradient between a buffer A of 98% Water, 2% (v/v) Acetonitrile and 0.1% (w/v) 
Formic Acid and a buffer B of 80% Acetonitrile, 20% Water, 0.1% Formic Acid. Sample 
peptides were re-suspended in a buffer of 4% v/v Acetonitrile and 0.1% Formic Acid and 
injected in duplicate. An Eksigent system comprising of a nanoLC 400 autosampler along 
with a 425-pump module were used with a YMC-Triart C18 trap column and a YMC-
Triart C18 analytical column. Mass spectra were obtained in SWATH mode and utilising 
the 100 variable window methods with optimised collision energy equations.  
The resultant spectral data files were converted using wiffconverter (Sciex, Warring-
ton, UK)” and searched against our consensus spectral library using OpenSwath (version 
2.0.0). Peptide matches were statistically scored using pyProphet (version 0.18.3) within 
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the TransProteomic Pipeline (TPP) and then aligned using the TRIC tool from the Open-
SWATH pipeline. 
Downstream statistical analysis was performed using the Bioconductor (release 3.5) 
packages SWATH2Stats and MSstats within the R language (version 3.4.1). Gene ontology 
analysis was conducted using the webserver, WebGestalt [22]. Potential contaminants and 
decoy sequences were excluded prior to all analyses. To provide further insights into the 
nature of the spectral libraries, we produced sub-libraries based on specific sample types, 
thus allowing for comparison between libraries. 
3. Results 
3.1. Descriptive Characteristics of the Study Population 
The demographic and clinical characteristics of the women whose cervico-vaginal 
fluid samples were used for the spectral library generation are summarised in Table 2. 
Cervico-vaginal samples from 19 women, comprising 9 EC cases, 3 AH’s and 7 controls, 
were used to generate the library. Five of the cases were endometrioid in histology while 
the remainder were non-endometrioid and included serous, clear cell, carcinosarcoma 
and mixed histology. All participants in this cohort were post-menopausal, with median 
age and BMI of 60 years (interquartile range, IQR 54–73 years) and 29 kg/m2 (IQR 27–38 
kg/m2) respectively. 





(kg/m2) Diagnosis Grade Stage 
Library Generation Cohort 
1 57 38 Atypical Hyperplasia - - 
2 78 45 Atypical Hyperplasia - - 
3 61 37 Atypical Hyperplasia - - 
4 65 27 Endometrioid Endometrial cancer  1 1A 
5 60 43 Endometrioid Endometrial cancer 1 1A 
6 73 29 Endometrioid Endometrial cancer 2 1A 
7 52 30 Endometrioid Endometrial cancer 2 1A 
8 62 27 Clear Cell Endometrial cancer 3 1A 
9 52 30 Serous Endometrial cancer 3 1A 
10 74 27 Carcinosarcoma 3 1B 
11 72 27 Mixed (Clear Cell/Endometrioid) cancer 3 2 
12 84 28 Endometrioid Endometrial cancer 3 4B 
13 54 29 Control (No endometrial pathology) - - 
14 81 24 Control (No endometrial pathology) - - 
15 56 24 Control (Atrophic vaginitis) - - 
16 56 40 Control (No endometrial pathology) - - 
17 52 44 Control (No endometrial pathology) - - 
18 50 24 Control (No endometrial pathology) - - 
19 56 24 Control (No endometrial pathology) - - 
3.2. The Spectral Libraries 
The consensus cervico-vaginal fluid spectral library contains a total of 154,206 tran-
sitions and 23,886 precursors identifying 19,394 peptides and 2425 proteins. The spectral 
library based on the EC cell lines, on the other hand, comprised 221,844 transitions, 30,876 
precursors, 29,384 peptide sequences and 6003 proteins. The coverage and characteristics 
of these assays are summarised in Table 3 and Figure 3. 
As expected, the cervico-vaginal fluid library precursor ion m/z ranged between 400 
m/z and 1200 m/z (median 726.3 m/z), in keeping with the MS mass range settings. A mass 
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window of 400 to 1200 Da (m/z) is commonly employed in SWATH/DIA-MS analysis in 
order to obtain a full coverage of peptides. The product ion m/z, on the other hand, ranged 
between 350 m/z and 1998 m/z (median of 915 m/z). About 56% (13,401) of the precursor 
ions were doubly charged and the remainder (10 485, 43.9%) had a charge of 3. The frag-
ment ions were mostly y type (132, 043, 85.6%) and singly charged (132, 038, 85.6%). The 
median peptide length of the peptide sequences was 15 amino acids (IQR 12, 19), and is 
consistent with the properties of full tryptic peptides. The average number of peptides per 
protein was 8 (median 2). Protein identification was based on the presence of a proteotypic 
peptide in 76% (1837) of proteins. The EC cell line-based assay had many properties sim-
ilar to the cervico-cervico-vaginal fluid spectral library. The median peptide length of the 
cell line library was 13 amino acids (range 7–49, IQR 6) with 75% of peptide sequences 
having a length between 7 and 17. The median number of peptides per protein was 3. 
Approximately 75% of the cell lined based precursor ion m/z and product ion m/z ranged 
between 400–890 m/z and 350–1235 m/z respectively. Most precursor ions also had a 
charge of 2 while majority of the fragment ions were singly charged. 
 
Figure 3. Overview of the cervico-vaginal fluid (CVF) and the EC cell-line (CL) based spectral library 
properties (A) histogram of the precursor ions m/z distribution of the CVF library (B) histogram of 
the precursor ions m/z distribution of the CL library (C) histogram of protein identifications based 
on the number of peptides per protein for both libraries (D) histogram of the peptide length distri-
bution for both libraries. 
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Table 3. Assay statistics for the consensus cervico-vaginal fluid and endometrial cancer cell-based 
spectral libraries at a protein FDR of 1%. 
Assays Proteotypic Proteotypic and Shared 
Consensus cervico-vaginal fluid spectral library 
Proteins 1836 2425 
Peptides 18,247 19,394 
Precursors 22,455 23,886 
Transitions 144,060 154,206 
Endometrial cancer cell-line based spectral library 
Proteins 5140 6003 
Peptides 27,972 29,384 
Precursors 29,509 30,876 
Transitions 209,988 221,844 
The cervico-vaginal fluid library includes a broad spectrum of regulatory, cytoskele-
tal and immune proteins. The gene ontology classification of the constituent proteins 
based on protein class, biological function, and molecular properties are summarised in 
Figure 4. Most of the library proteins had binding, structural and regulatory properties 
mediating cellular and metabolic functions. Approximately 50% of proteins were extra-
cellular in origin. 
  
Figure 4. Gene ontological analyses of the cervico-vaginal fluid library proteotypic proteins mapped using the WebGestalt 
[22] Webserver, Available online: www.webgestalt.org (accessed on 10/05/2021). The biological processes (A), cellular pro-
cesses (B) and molecular function categories (C) are as shown. The height of each bar represents the number of mapped 
IDs per category. 
The cervico-vaginal fluid and cell line spectral libraries showed a 20% commonality 
(1186) in identified proteins. About 11.2% (650) proteins were found to be unique to the 
cervico-vaginal fluid library (Figure 5A). These proteins were noted to be extracellular in 
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origin and with immune-related and acute inflammatory properties (Figure 5B). A Venn 
diagram showing the overlap between both spectral libraries and the Pan Human library 
is shown in Figure 5B. Both spectral libraries captured 53% (5503) of the pan Human li-
brary proteins. The cervico-vaginal fluid spectral library contained 202 distinct proteins 
not present in the pan Human library while the cell line-based library contained 105 dis-
tinct proteins (Figure 5C). Gene Ontology analysis of the cervico-vaginal proteome unique 
proteins is shown in Figure 5D and reveals leucocyte migration, regulation of humoral 
immune response and cornification as their main biological functions. Gene names of pro-
teins unique to the cervico-vaginal fluid library compared with the pan Human library 
are summarized in Table S1. 
The cervico-vaginal fluid consensus spectral library comprised of proteins originat-
ing from the supernatant and cell pellet components of the cervico-vaginal fluid obtained 
from symptomatic controls, women with AH and EC. A Venn diagram showing the con-
tribution of these various components in the generated library is shown in Figure 6. We 
found a total of 269 proteins to be unique to the cancer supernatant samples and 92 pro-
teins to the cancer pellet samples. 37 unique proteins overlapped between the cancer pel-
lets and supernatants. 31 proteins were unique to the AH supernatant samples and 73 
proteins to the AH pellet samples.  
  
Figure 5. (A): Venn diagram showing overlap between the cervico-vaginal fluid and the cell line spectral libraries. (B). 
Gene ontological analysis (biological function) of the 650 proteins unique to the cervico-vaginal fluid library. (C). Venn 
diagram showing overlap between the cervico-vaginal fluid, EC cell line and pan Human libraries. (D). Gene ontological 
analysis (biological function) of the proteins unique to the cervico-vaginal fluid library. All analyses were based on prote-
otypic proteins. 
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Figure 6. (A) Overview of the overlap of the various components that make up the consensus cer-
vico-vaginal fluid library. AP: Atypical hyperplasia cell pellets, AS: Atypical hyperplasia superna-
tant, CaS: Cancer supernatant, CaP: Cancer pellets, CoS: Control Supernatant, CoP: Control pellets. 
All analyses were conducted based on proteins identified by proteotypic peptides. (B) Overview of 
the overlap between the cervico-vaginal fluid consensus spectral library and the cervico-vaginal 
fluid proteome described by Zegels et al. and Tang et al. respectively. 
Next, we sought to compare the coverage of our cervico-vaginal fluid spectral library 
with the cervico-vaginal fluid proteome reported in previous studies. We did not identify 
any studies describing the cervico-vaginal fluid proteome of post-menopausal women 
with or at risk of endometrial cancer. A comparative overview of the various studies con-
ducted on the cervico-vaginal fluid proteome in non-pregnant females is summarised in 
Table 4. A Venn diagram of the overlap between our spectral library and two other cer-
vico-vaginal fluid proteome studies in non-pregnant women is shown is Figure 6. Our 
cervico-vaginal fluid library captured approximately 75% of the proteins described by Ze-
gels et al. [23] and 76% of the 59 unique cell-free cervico-vaginal fluid proteins described 
by Tang et al. [24]. We were unable to assess the coverage of the proteome described by 
Shaw et al. due to lack of relevant data. Previously reported EC biomarker candidates 
captured in the library are summarised in Table S1, while other tumour-related proteins 
captured in the library are summarised in Table S2. 
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Table 4. Comparative overview of the various studies on the cervico-vaginal (CVF) proteome conducted in non-pregnant 
women. 
Study Characteristics Our CVF Spectral Library CVF Proteome by Zegel et al. [23] 
CVF Proteome by Tang 
et al. [24] 
CVF Proteome by Shaw et 
al. [25] 
Sample size 19 7 29 5 
Age range 50–67 years 37–45 years 24–48 years 20–40 years 
Menopausal status Post-menopausal  Pre-menopausal Pre-menopausal Pre-menopausal 
Clinical diagnoses 9 EC cases, 3 AH and 7 symp-
tomatic women with no EC 
All had cervical pre-can-
cer 
Asymptomatic women, 7 
had candida 
Healthy female volunteers 
Sample collection Delphi screener 
(saline based wash) 
Colposcopy 
(5% acetic acid wash) 
Syringe 
(saline based wash) 
Gauze 
(inserted in vagina for 1 h) 
Sample description Supernatant and pellets Supernatant only Supernatant only Whole fluid 








Protein identification X!Tandem  MASCOT MASCOT MASCOT & X!Tandem 
Spectral library pro-
tein count 2425 339 147 (59 unique) 685 
3.3. Spectral Library Validation 
The library validation was carried out using cervico-vaginal fluid samples obtained 
from an independent cohort of women and comprised of five women at-risk of EC (tech-
nical validation) and ten women, including five with histologically confirmed EC and five 
controls (clinical validation). The technical validation cohort had a median age and BMI 
of 55 years (IQR 51–56 years) and 34 kg/m2 (19–37 kg/m2) respectively while the clinical 
validation cohort had a median age and BMI of 58 years (IQR 52–62 years), and 32 kg/m2 
(27–36 kg/m2) respectively. The demographic and clinical characteristics of the validation 
cohorts are summarised in Table 5. 
Table 5. Demographic and clinical characteristics of the technical and clinical validation cohorts. 




Diagnosis Grade Stage 
   Technical Validation Cohort   
20 50 19 Control (No endometrial pathology)   
21 52 37 Control (Benign endometrial polyp)   
22 55 34 Control (No endometrial pathology)   
23 56 19 Control (No endometrial pathology)   
24 56 37 Control (No endometrial pathology)   
   Clinical Validation Cohort   
25 58 36 Atypical Hyperplasia - - 
26 67 30 Endometrioid endometrial cancer 1 1A 
27 55 34 Endometrioid endometrial cancer 1 1A 
28 50 54 Endometrioid endometrial cancer 1 1A 
29 62 27 Clear cell 3 1A 
30 60 58 Control (No endometrial pathology) - - 
31 62 24 Control (Atrophic vaginitis) - - 
32 58 30 Control (Benign endometrial polyp) - - 
33 47 24 Control (No endometrial pathology) - - 
34 52 33 Control (No endometrial pathology) - - 
3.3.1. Technical Validation and Applicability for SWATH-MS Data Analysis 
We searched our library using five cervico-vaginal fluid samples obtained from an 
independent cohort of post-menopausal women at-risk of EC (Table 5) and processed us-
ing standard SWATH-MS protocol, to assess the performance of our library. Each sample 
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was run in duplicate. We evaluated the extent to which biological replicates were repro-
ducible based on our spectral library using correlation analyses of normalised replicate 
values as shown in Figure 7. There was a very strong evidence of intensity correlation 
between sample replicates with Pearson’s correlation coefficient values of ≥0.98.  
 
Figure 7. Technical validation and applicability of consensus cervico-vaginal fluid spectral library based on five samples 
obtained from an independent cohort of post-menopausal women at risk of endometrial cancer. Scatter plots of intensity 
correlation between replicates of all five validationsamples (A–E) using Pearson’s correlation analyses are as shown. 
The reproducibility of peptide identifications was subsequently summarised using 
coefficient of variations of transition intensities at a 1% peptide FDR. The median intra-
assay coefficient of variation for all replicates were <10 and is in keeping with expected 
technical variability (Figure 8).  




Figure 8. (A) Intra-assay coefficient of variation across validation samples (B) Summary coefficient of variation comparing 
total versus within replicates. 
High rates of missingness are a major concern in proteomic studies [26,27]. We there-
fore sought to assess the rate of missing values between technical replicates of the same 
samples (Table 6). On average, the percentage of missing values in technical replicates 
was <10% and compares favorably to DDA proteomics where rates of missingness of at 
least 20% have been reported [28]. The overall rate of missingness per sample ranged be-
tween 12.9% and 21.8%, and is consistent with other label free mass spectrometry methods 
with rates of 10–50% [26,29]. 
Table 6. Missing values between technical replicates of the same cervico-vaginal fluid samples. 
Sample Protein Count Missing Values in 
Replicate 1 
Missing Values in 
Replicate 2 
Overall Rate 
Sample 1 410 21(5.1%) 32(7.8%) 12.9% 
Sample 2 389 25(6.4%) 28(7.2%) 13.6% 
Sample 3 308 37(12.0%) 30(9.7%) 21.8% 
Sample 4 378 29(7.7%) 33(8.7%) 16.4% 
Sample 5 426 25(5.9%) 35(8.2%) 14.1% 
3.3.2. Real World Application of Spectral Library for Biomarker Discovery 
Next, we sought to provide evidence for the potential utility of our consensus spec-
tral library for EC biomarker discovery in the real-world setting. Cervico-vaginal fluid 
samples from five cancer cases and five controls were processed and analysed in duplicate 
using our previously described standardised SWATH-MS protocol. The demographic and 
clinical characteristics of this validation cohort are summarised in Table 5. We then 
searched the obtained dataset against our consensus spectral library. Globally, a total of 
680 proteins based on proteotypic peptides were identified in our validation dataset. The 
numbers of proteins quantified per sample replicate is summarised in Figure 9A, with 
identified protein counts ranging from 199 to 447. A Log2 intensity plot of sample repli-
cates is shown in Figure 9B, with intensity correlation coefficients ranging from 0.95 to 
0.99 (Figure S1). The coefficient of variations of transition intensities between replicates is 
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summarised in Figure S2 with median CVs ranging from 7.8 to 10.9, in keeping with ex-
pected technical variations.  
  
Figure 9. Real world application of spectral library for biomarker discovery based on cervico-vaginal fluid samples from 
five cancers and five controls. (A) Number of quantified proteins per study sample replicate. (B) Log 2 Intensity plot of 
corresponding sample replicates. 
Principal component analysis (PCA) and t-distributed stochastic neighbour embed-
ding (t-SNE) plots were then used to assess degree of separation between groups and 
shown in Figure 10. The list and gene ontology analyses of the cervico-vaginal fluid pro-
teins from the validation cohort used in generating the PCA and t-SNE plots are summa-
rized in Table S2 and Figure S3 respectively. The differentially expressed proteins between 
the 5 cancer and 5 control samples are summarized in Table S3. Next, we selected five EC 
biomarker candidates previously reported in the literature and assessed how well the 
spectral library could reproducibly quantify them. The selected biomarkers were Human 
Epididymis Protein 4 (HE4/WFDC2), Cancer Antigen 15-3 (MUC 1), Matrix metallopro-
teinase 9, Fatty Acid Binding Protein-5 (FABP5) and Alpha-1B-Glycoprotein. All five bi-
omarker candidates were reproducibly quantified with replicate intensity correlation co-
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efficients of 0.99 respectively. The coefficient of variation across replicates of these bi-
omarker candidates ranged from 0.62 to 4.88, again, in keeping with expected technical 
variations. (Table 7). 
 
 
Figure 10. Analysis of sample separation comparing five EC cases and five controls using principal component analysis 
(PCA) (A) and t-distributed stochastic neighbour embedding (t-SNE) (B) plots based on differentially expressed cervico-
vaginal fluid proteins. 
Table 7. Reproducibility of selected biomarker candidates using the consensus cervico-vaginal fluid 
spectral library. 
Biomarker Candidate Gene Name Intensity Correlation Coefficient 
Coefficient of 
Variation 
Human Epididymis Protein 4 HE4/WFDC2 0.99 3.29 
Cancer Associated Antigen 15-3 MUC-1 0.99 4.88 
Matrix Metalloproteinase 9 MMP9 0.99 2.01 
Fatty Acid Binding Protein-5 FABP5 0.99 0.62 
Alpha-1B-Glycoprotein AIBG 0.99 1.36 
Finally, we sought to describe the dynamic range of the cervico-vaginal fluid prote-
ome by ranking all identified proteins (log 10 mean protein intensity) in the validation 
cohort according to their abundance (Figure 11A). The cervico-vaginal fluid proteome 
spans about four orders of magnitude, in keeping with the proximal nature of the cervico-
vaginal fluid and in contrast to the dynamic range of cancer-related proteins in blood, 
which is wider (plasma dynamic range ≥10 orders of magnitude) [30]. Next, we computed 
the dynamic ranges of individual proteins detected in the validation cohort based on the 
ratio of the maximum and minimum log10 protein intensities (Figure 11B). The identified 
proteins have dynamic range values ranging from 1.002 to 2.50 (SD 0.26) orders of mag-
nitude. 




Figure 11. (A) Dynamic range of the cervico-vaginal fluid proteome based on the rank by abundance of the log10 intensity 
of all identified proteins in the validation cohort. (B) Dynamic ranges of individual proteins detected in the validation 
cohort based on the ratio of the maximum and minimum log10 protein intensities. 
4. Discussion 
Proteomic analysis of human biological fluids has the potential to facilitate the dis-
covery of clinically relevant biomarkers [31]. Cervico-vaginal fluid is a complex mixture 
of vaginal, endocervical, endometrial and fallopian tube secretions. Other components of 
cervico-vaginal fluid include exfoliated cells, commensal bacterial products, plasma tran-
sudate through the vaginal wall and secretions from vaginal immune cells [32]. Cervico-
vaginal fluid exhibits antimicrobial properties and plays an important role in the immun-
ity of the lower female genital tract. It is also responsible for maintaining homeostasis of 
the vaginal micro-environment [33,34]. Multiple studies have explored the potential of 
cervico-vaginal fluid to aid the detection of pregnancy associated pathologies such as pre-
term birth [35–38], inflammatory/infective conditions of the lower genital tract [39,40] and 
cervical pre-cancer [41–43]. The anatomical continuity between the uterine cavity and the 
lower genital tract provides an opportunity for the sampling of uterine derived proteins 
and malignant cells using minimally invasive methods [13,44]. A recent study from our 
group showed proof-of-principle that cervico-vaginal fluid from women with EC contains 
malignant cells and is a viable source of EC biomarkers [45]. However, the potential utility 
of cervico-vaginal fluid as a source of protein biomarkers for the detection of EC, has been 
under-studied. 
To our knowledge, our cervico-vaginal fluid consensus spectral library is the first 
and most comprehensive catalogue of proteins in cervico-vaginal fluid of women with or 
at-risk of EC. We identified 2425 proteins in pooled cervico-vaginal samples covering the 
full spectrum of EC, from symptomatic post-menopausal women, with no evidence of 
cancer, to those with AH and early and late-stage EC. Both endometrioid and non-endo-
metrioid tumours were reflected in the library. The consensus library was built based on 
cervico-vaginal fluid supernatant proteins and proteins originating from exfoliated 
cells/endometrial malignant cells shed through the cervix into the lower genital tract [45]. 
The subsequent validation of the library using cervico-vaginal fluid samples from an in-
dependent cohort of women showed the library to be fit-for-purpose. Importantly, the 
library was robust in reproducibly quantifying selected EC biomarker candidates. Our 
library thus has the potential to enable the identification of protein biomarkers for the 
screening and early detection of EC. 
Our cervico-vaginal fluid consensus spectral library makes an important contribu-
tion, in that over 200 proteins were found to be unique to this library, when compared 
with the Pan Human library. We did not find any previous studies describing the cervico-
vaginal proteome of post-menopausal women or those with EC. A comparison with two 
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previously reported comprehensive studies on the cervico-vaginal fluid proteome 
showed our cervico-vaginal fluid library capturing approximately 75% of the proteins de-
scribed by Zegels et al. [23] and 76% of the 59 unique cell-free cervico-vaginal fluid pro-
teins described by Tang et al. [24]. In addition, a large number of proteins were noted to 
be unique to our spectral library when compared with both previously reported proteo-
mes. The Zegels study was relatively small, with just seven women, aged between 37 and 
45 years, all of whom were either in the first- or second half of the menstrual cycle and 
with cervical pre-cancer (low-grade squamous intra-epithelial cervical lesions) [23]. The 
proteins unique to Zegels cervico-vaginal fluid proteome may therefore be related to the 
pre-menopausal status of the study participants or the presence of cervical pre-cancer. 
Tang et al., on the other hand, collected samples from 29 women, aged 24–48 years, seven 
of whom had evidence of candida [24]. Shaw and colleagues, using five clinical samples, 
characterised the cervico-vaginal proteome of young, healthy pre-menopausal women 
and identified 685 proteins, 30% of which were extracellular or membrane in origin [25]. 
A few other studies have explored the cervico-vaginal fluid proteome, but these have 
largely been in the context of menstrual cycle changes, pregnancy or cervical pre-cancer 
[23,25,46–48]. 
Our cervico-vaginal fluid consensus spectral library captures a broad range of pro-
teins, many of which have previously been reported as EC biomarker candidates (Table 
S4). Of particular interest are the heat shock proteins/chaperones (hsp10, hsp60, hsp71, 
hsp75), a group of proteins that regulate protein folding and cell signalling and have been 
implicated in the proliferation and differentiation of tumour cells [49]. There is good evi-
dence to suggest that these proteins are over-expressed in EC tissue specimens, although 
their utility as EC biomarkers may be limited by their non-specificity [50–52]. Other tissue-
based EC biomarker candidates previously reported in the literature and captured in the 
library include calcium binding proteins (calgranulin (S-100A8/9), fatty acid binding pro-
teins (putative fatty acid-binding protein 5-like protein 3), glycolytic enzymes (pyruvate 
kinase, Phosphoglycerate mutase 1, Alpha-enolase) and enzyme inhibitors (alpha1 an-
titrypsin). Calcium and fatty-acid binding proteins are involved in cell differentiation, 
proliferation, migration and apoptosis, while the over-expression of glycolytic enzymes 
in EC tissue specimens is linked to their role in generating ATP during cell proliferation 
[53,54]. 
Several plasma-based EC biomarker candidates were also captured in this library and 
include adipokines (e.g., adiponectin), plasma lipoproteins (apolipoproteins, plasma am-
yloid A), matrix metalloproteinases (MMP-9) and cancer-associated antigens (MUC 1, 
MUC 16 etc). Other plasma proteins include human epididymis protein-4 (HE-4), Alpha-
1B-Glycoprotein, albumin, transferrin and immunoglobulins. The presence of these pro-
teins in the cervico-vaginal fluid may relate to the transudation of plasma from the capil-
laries in the vaginal epithelium. A number of tumour related proteins were also noted 
(Table S5). As expected, proteins with antimicrobial functions were well represented in-
cluding neutrophil defensins, cysteine-rich secretory protein 3, dermcidin, cathelicidin an-
timicrobial peptide, amongst others, as well as inflammatory markers such as C-reactive 
protein.  
This study has several strengths. Our spectral library reflects the full spectrum of EC 
and thus has the potential to identify and quantity both early (AH/stage 1A EC) and late-
stage EC protein biomarkers. Early detection of EC is crucial for improved outcomes 
[13,55,56]. A recent study exploring the unmet research needs in EC found a detection tool 
that can triage symptomatic women for specialist review to be the 2nd most important 
research priority according to patients, carers and clinicians [57]. A similar study using 
James Lind Alliance methodology ranked “What simple, non-invasive, painless, cost-ef-
fective, and convenient tests can be used to detect cancer early?” first in the top ten re-
search priorities for cancer early detection [58]. Whilst a detection tool based on SWATH-
MS analysis of cervico-vaginal fluid samples may not be easily translated into routine 
clinical practice, it can pave the way for the development of a clinically tractable assay 
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based on ELISA or Lumipulse ® technology, or even lateral flow test technology for point 
of care testing. This approach can lead to rapid discrimination of cases and controls, with 
substantial cost-saving implications for healthcare providers, whilst saving women from 
invasive tests that are anxiety-provoking and avoidable in over 90% of cases.  
The validity and reliability of cervico-vaginal fluid sampling methodology directly 
influences the quality of cervico-vaginal fluid -based assay libraries. Of the four com-
monly used cervico-vaginal fluid collection methods, namely washings, swabs, wicks (in-
cluding tampons) and diaphragm-like devices, cervico-vaginal washings, as used in this 
study, has shown superiority in terms of reproducibility and sample quality [59,60]. How-
ever, relevant markers are diluted in the washing buffer and sample optimization steps 
are often necessary during proteome assay development. Cervico-vaginal fluid collection 
using the Delphi device achieved excellent acceptability by patients [45,61] and ongoing 
work by our group is assessing it’s acceptability to practice nurses and general practition-
ers. Other strengths of this study include the choice of our control group which comprised 
women from a similar at-risk population as those with EC (i.e., symptomatic post-meno-
pausal women) but who do not have EC. This constitutes the ideal control group for EC 
biomarker discovery studies, especially when compared to studies where healthy women, 
usually of younger age and without the symptom that needs investigating by the new test, 
are used as controls. Limitations of our study design include the relatively small number 
of representative samples of the various EC subtypes and stages. Also, we do not know 
how well the library will perform in identifying and quantifying relevant biomarkers in 
asymptomatic women or pre-menopausal women with hereditary predisposition to EC, 
as seen in Lynch syndrome. The differentially expressed proteins in the cervico-vaginal 
fluid of the five cancers and five controls are yet to be validated by immunoassays or 
targeted proteomics. Caution must be entertained when interpreting these results. 
In order to enhance the utility of these datasets, we have provided relevant anony-
mised clinical and demographic information of the patient cohort whose samples were 
used in generating the library including age, tumour type, grade and stage. Our cell-line 
based library was built using Ishikawa and HEC-IA cell lines, representing pre- and post-
menopausal endometrial cancer, respectively. Using the deposited data, bespoke cell-line 
spectral libraries that reflect the menopausal status of study participants may be recreated. 
Our datasets can be used to enrich and improve the comprehensiveness of other proteo-
mic spectral libraries specifically tailored for the detection of gynaecological malignancies 
based on cervico-vaginal fluid sampling. The data set can also be further analysed using 
other state-of-the-art analytical software and may be integrated into larger EC related pro-
teomic datasets and/or publically available protein libraries. 
Our samples were processed using a TEAB lysis buffer and TCEP based digestion 
protocol. The generated library is compatible with other protocols, provided that lysis is 
complete, and reduction and alkylation of cysteine bonds are ensured. Although our li-
brary was generated based on 100 variable windows with selection of the six most intense 
fragment ions, spectral libraries based on a different window configuration and transition 
selection can be made using the deposited data. Furthermore, although the library was 
generated based on DDA data from an Orbitrap Fusion Lumos Tribrid mass spectrometer, 
it can still be used for data generated on different instruments. However, retention times 
will need to be re-aligned and collision energy settings optimised. Inclusion of iRT pep-
tides [62,63] as commonly performed in DIA experiments gives opportunity in this respect 
to normalise data. Alternatively, conserved peptides can be used for retention time align-
ment [64]. Importantly, similarity of fragmentation spectra should be ensured by the op-
timization of collision energies. 
5. Conclusions 
In this study, we present the first comprehensive proteomic library with the potential 
to enable the identification and quantification of EC protein biomarkers in cervico-vaginal 
fluid. We identified 2425 proteins in pooled cervico-vaginal samples covering the full 
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spectrum of EC. This is combined with a library of over 6000 proteins based on two EC 
cell lines. The libraries capture a broad range of proteins, including previously reported 
tissue and plasma-based EC biomarker candidates. Several proteins were noted to be 
unique to the consensus library when compared with both the Pan Human library and 
previously reported studies on the cervico-vaginal fluid proteome. Subsequent technical 
and clinical validation of the library using cervico-vaginal fluid samples from an inde-
pendent cohort confirmed the library to be fit-for-purpose. Well-designed biomarker dis-
covery studies with adequate sample sizes based on the use of SWATH-MS on cervico-
vaginal fluid samples of women with and at-risk of EC are now needed to identify rele-
vant biomarkers that can be translated into routine clinical practice. 
Supplementary Materials: The following are available online at www.mdpi.com/arti-
cle/10.3390/cancers13153804/s1. Figure S1: Intensity correlation coefficient values of the clinical val-
idation cohort sample duplicates. Figure S2: The coefficient of variations of transition intensities 
between replicates for the clinical validation cohort. Figure S3: Gene ontology analyses of cervico-
vaginal fluid proteins from the validation cohort used in generating the PCA and TSNE plots. Table 
S1: Gene names of proteins unique to cervico-vaginal fluid library compared to the pan-human li-
brary. Table S2: List of proteins detected in the cervico-vaginal fluid of the validation cohort and 
used for the PCA plots and TSNE plots in Figure 10. Table S3: Differentially expressed proteins 
between the five cancers and five controls used for library validation. Table S4: Previously reported 
EC biomarker candidates captured in the library. Table S5: Novel tumour related proteins captured 
in the library.  
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